Beam Therapeutics (BEAM) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
3 Nov, 2026Executive summary
Q3 net loss widened to $134.4M from $112.6M year over year as revenue fell and operating expenses rose; BEAM-302 and BEAM-301 reported encouraging efficacy signals.
Cash, cash equivalents and marketable securities totaled $1.044B at September 30, 2026; runway is expected into mid-2029, subject to conditions on additional borrowings.
Clinical progress spanned BEAM-302, BEAM-301, BEAM-304 and risto-cel, with a potential U.S. BLA filing for risto-cel as early as year-end 2026.
Financial highlights
Q3 license and collaboration revenue was $0.3M versus $9.7M; R&D expense was $110.1M versus $109.8M and G&A was $31.5M versus $26.7M year over year.
Q3 operating loss was $141.3M versus $126.8M; net loss was $134.4M, or $1.28 per share, versus $112.6M, or $1.10 per share.
9M revenue was $32.5M versus $25.6M, primarily reflecting a $25.0M Lilly milestone; operating expenses were $407.6M versus $391.9M and net loss was $351.4M versus $323.0M.
9M operating cash use was $305.4M versus $261.8M; cash, cash equivalents and restricted cash ended at $220.0M.
Outlook and guidance
Updated risto-cel data and a U.S. BLA submission are expected by year-end 2026, with filing possible as early as year-end.
BEAM-302 pivotal-cohort dosing is expected to complete in H1 2027; its Phase 1/2 trial is designed to support a potential U.S. accelerated approval path.
BEAM-304 Phase 1/2 dosing is expected to begin in early 2027, initially targeting patients with the R408W mutation in PKU.
Cash and marketable securities are expected to fund operations and planned development into mid-2029, including $200M expected from the Sixth Street facility subject to borrowing conditions.
BEAM-301 enrollment is proceeding in a 60 mg cohort, with FDA discussions planned on a potential regulatory approval path.
Latest events from Beam Therapeutics
- BEAM-302 advances toward pivotal follow-up as risto-cel targets a December 2026 BLA.BEAM
Jefferies Global Healthcare Conference - Positive sickle cell results, advancing AAT enrollment and striking early GSD1a data drive the pipeline.BEAM
UBS Global Biopharma Conference 2026 - Risto-cel nears BLA filing as in vivo editing programs advance.BEAM
3rd Annual Guggenheim Healthcare Innovation Conference - Two of three patients at 40 mg reached 15-hour fasting and stopped starch supplementation.BEAM
Study result - Gene editing pipeline advances with durable results, strong safety, and first-mover advantage.BEAM
12th Annual Cantor Fitzgerald Global Healthcare Conference - Advancing curative gene therapies with strong financials and pivotal clinical milestones in 2026.BEAM
Corporate presentation - BEAM-302 gene editing achieved sustained, functional AAT restoration and was well tolerated.BEAM
European Respiratory Society Congress presentation - Advancing pivotal gene editing programs with strong data, regulatory momentum, and platform scalability.BEAM
Citigroup’s Biopharma Back to School Summit 2026 - Durable AAT restoration and >80% Z-AAT reduction advance toward pivotal approval.BEAM
Status update